Alzheon
Alzheon develops drugs against Alzheimer's disease and other disorders. Its ALZ-801 medication is going through the third phase of clinical trials. The company is headquartered in Framingham, Massachusetts.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
News related to Alzheon50
Alzheon to Present Phase 2 Biomarker Trial Results and Baseline ...
Alzheon, Inc. is a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from ...
https://www.morningstar.com/news/business-wire/20240723403529/alzheon-to-present-phase-2-biomarker-trial-results-and-baseline-characteristics-from-apolloe4-phase-3-trial-of-oral-alz-801valiltramiprosate-in-patients-with-early-alzheimers-disease-at-alzheimers-association-international-conferenceAlzheon to Present Phase 2 Biomarker Trial Results and Baseline ...
Alzheon to Present Phase 2 Biomarker Trial Results and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in Patients with ...
https://finance.yahoo.com/news/alzheon-present-phase-2-biomarker-100000205.htmlAlzheon Announces Appointment of Renowned Biopharma ...
Alzheon Announces Appointment of Renowned Biopharma Executive Gino Santini to Board of Directors...
https://finance.yahoo.com/news/alzheon-announces-appointment-renowned-biopharma-100000749.htmlAlzheon Announces Appointment of Renowned Biopharma ...
Alzheon, Inc. is a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from ...
https://www.morningstar.com/news/business-wire/20240612795015/alzheon-announces-appointment-of-renowned-biopharma-executive-gino-santini-to-board-of-directorsAlzheon Announces First Patient Dosed in Long-Term Extension of ...
"At Alzheon, we always put patients first, so we are pleased to offer subjects in our Alzheimer's studies who have completed the APOLLOE4 Phase 3 trial or the ...
https://finance.yahoo.com/news/alzheon-announces-first-patient-dosed-100000386.html